Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare

Nature Biotechnology

Volumn 21, Issue 7, 2003, Pages 747-753

  Shah, Jai ^a  

^a CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; ECONOMICS; LAWS AND LEGISLATION; PHARMACODYNAMICS; REGULATORY COMPLIANCE;

DRUG APPROVAL;

BIOTECHNOLOGY;

DRUG APPROVAL; DRUG LEGISLATION; DRUG MARKETING; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEALTH CARE SYSTEM; LICENSING; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

CANADA; COST-BENEFIT ANALYSIS; DRUG APPROVAL; GOVERNMENT REGULATION; HEALTH CARE SECTOR; LEGISLATION, DRUG; LIABILITY, LEGAL; LICENSURE; ORPHAN DRUG PRODUCTION; PHARMACOGENETICS; UNITED STATES;

EID: 0038730474     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0703-747     Document Type: Review

References (52)

1. Lindpaintner, K. Pharmacogenetics and the future of medical practice: conceptual considerations. Pharmacogenomics J. 1, 23-26 (2001).
2. Tollman, P., Guy, P., Altshuler, J., Flanagan, A. & Steiner, M. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry(The Boston Consulting Group, Boston, MA, 2001).
3. Snedden, R. Pharmacogenetics Workshop: Background Paper (The Wellcome Trust, London, 1999).
4. Hodgson, J. & Marshall, A. Pharmacogenomics: will the regulators approve? Nat. Biotechnol. 16, 243-246 (1998).
5. Robertson, J.A., Brody, B., Buchanan, A., Kahn, J. & McPherson, E. Pharmacogenetic challenges for the health care system. Health Aff. 21, 155-167 (2002).
6. Ledley, F.D. Can pharmacogenetics make a difference in drug development? Nat. Biotechnol. 17, 731 (1999).
7. Lindpaintner, K. The importance of being modest: reflections on the pharmacogenetics of Abacavir. Pharmacogenomics 3, 835-838 (2002).
8. Thomas, S.M. Pharmacogenetics: the ethical context. Pharmacogenomics J. 1, 239-242 (2001).
9. Lindpaintner, K. Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex diseases. Br. Med. Bull. 55, 471-491 (1999).
10. Roses, A.D. Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
11. Norton, R.M. Clinical pharmacogenetics: applications in pharmaceutical R&D. Drug Discov. Today 6, 180-186 (2001).
12. Owens, J., Ramster, B. & Lawrence, R.N. Impact of SNP genotyping could save millions by 2010. Drug Discov. Today 6, 450 (2001).
13. Birmingham, K. Experts predict bleak post-genomic era for drug R&D. Nat. Med. 7, 262 (2001).
14. Hawkes, N. Medicines priced high to recoup research and marketing cost. The Times, August 13 (2002), p. 4.
15. Lindpaintner, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463-469 (2002).
16. Ward, S.J. Impact of genomics in drug discovery. BioTechniques (Euro Edition), 64-69 (2001).
17. Rothstein, M.A. & Epps, P.G. Ethical and legal implications of pharmacogenomics. Nat. Rev. Genet. 2, 228-231 (2001).
18. Issa, A.M. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1, 300-308 (2002).
19. Spallone, P. & Wilkie, T. Social, Ethical, and Public Policy Implications of Advances in the Biomedical Sciences: The Wellcome Trust's Initiative on Pharmacogenetics (The Wellcome Trust, London, 1999).
20. Wolf, C.R. & Smith, G. Pharmacogenetics. Br. Med. Bull. 55, 366-386 (1999).
21. Broder, S. & Venter, J.C. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Annu. Rev. Pharmacol. Toxicol. 40, 97-132 (2000).
22. Borst-Eilers, E. Availability of pharmaceutical drugs. Lancet 356, 6 (2000).
23. Furberg, C,D., Herrington, D.M. & Psaty, B.M. Are drugs within a class interchangeable? Lancet 354, 1202-1204 (1999).
24. Shah, R.R. Regulatory aspects of integration of pharmacogenetics into drug development. Int. J. Pharmceut. Med. 15, 67-69 (2001).
25. US Food and Drug Administration. Improving innovation in medical technology: beyond 2002 (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2003/beyond2002/report.html (31 January 2003).
26. US Food and Drug Administration. FDA establishes office of combination products (USFDA, Rockville, Maryland)http://www.fda.gov/bbs/topics/NEWS/2002/NEW00862.html (31 December 2002).
27. Fogarty, M. Up for adoption: pharmacogenetics and the orphan drug law. HMS Beagle 44, http://news.bmn.com/hmsbeagle/, 11 December 1998.
28. Milne, C.-P. Orphan products - pain relief for clinical development headaches. Nat. Biotechnol. 20, 780-784 (2002).
29. Haffner, M.E., Whitley, J. & Moses, M. Two decades of orphan product development. Nat. Rev. Drug Discov. 1, 821-825 (2002).
30. Lesko, L. & Woodcock, J. Pharmacogenetic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 20-24 (2002).
31. Branca, M. FDA fosters pharmacogenomics. Bio-ITWorld, 1, 45 (2002).
32. US Food and Drug Administration. Gleevec approved for first line treatment of chronic myeloid leukemia (CML) (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2002/NEW0086O.html (20 December 2002).
33. McCarthy, M. FDA allows controversial bowel drug back on to market. Lancet 359, 2095 (2002).
34. US Food and Drug Administration. FDA approves restricted marketing of Lotronex (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2002/NEW00814.html (7 June 2002).
35. Lasser, K.E. et al. Timing of new black box warnings and withdrawals of prescription medications. JAMA 287, 2215-2220 (2002).
36. US Food and Drug Administration. FDA and Lincoln Technologies, Inc. to collaborate on developing tools for safety data mining. (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2003/NEW00899.htmi (1 May 2003).
37. Loyd, L. An end to vaccine for Lyme disease. The Philadelphia Inquirer, 27 February 2002, p. C1.
38. Editorial. Pharmacogenomics at work. Nat. Biotechnol. 16, 885 (1998).
39. Eggertson, L. Ontario defies US firm's genetic patent, continues cancer screening. Can. Med. Assoc. J. 166, 494 (2002).
40. Claxton, K., Schulpher, M. & Drummond, M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 360, 711-715 (2002).
41. Bloor, K., Maynard, A. & Freemantle, N. Lessons from international experiences in controlling pharmaceutical expenditure III: regulating industry. Br. Med. J. 313, 33-35 (1996).
42. National Institute for Clinical Excellence. Technology Appraisal Guidance No.34 - Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. (National Institute for Clinical Excellence, London, 2002).
43. Rennie, D. & Luft, H.S. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 283, 2158-2160 (2000).
44. BBC News Online. Relief over breast drug decision. British Broadcasting Corporation, http://news.bbc.co.uk/1/hi/health/1874368.stm, 15 March 2002.
45. BBC News Online. Two sides of the Herceptin lottery. British Broadcasting Corporation, http://news.bbc.co.uk/1/hi/health/1873433.stm, 15 March 2002.
46. Watanabe, M.E. Skeptical scientists skewer VaxGen statistics. Nat. Med. 9, 376 (2003).
47. Rothstein, M.A. & Epps, P.G. Pharmacogenomics and the (ir)relevance of race. Pharmacogenomics J. 1, 104-108 (2001).
48. Editorial, Genes, drugs and race. Nat. Genet. 29, 239-240 (2001).
49. Schwartz, R. S. Racial profiling in medical research. N. Engl. J. Med. 344, 1392-1393 (2001).
50. Wood, A.J.J. Racial differences in the response to drugs - pointers to genetic differences. N. Engl. J. Med. 344, 1393-1396 (2001).
51. Lipton, P. Pharmacogenetics: the ethical issues. Pharmacogenomics J. 3, 14-16 (2003).
52. Veenstra, D.L., Higashi, M.K. & Phillips, K.A. Assessing the cost-effectiveness of pharmacogenetics. AAPS Pharm Sci 2, E29 (2000).